NYSEAMERICAN:BPMX - Biopharmx Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.12 0.00 (0.00 %)
(As of 01/16/2019 12:51 PM ET)
Previous Close$0.1185
Today's Range$0.11 - $0.12
52-Week Range$0.05 - $0.38
Volume33,453 shs
Average Volume7.67 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.

Receive BPMX News and Ratings via Email

Sign-up to receive the latest news and ratings for BPMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:BPMX
CUSIPN/A
Phone+1-650-8895020

Debt

Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / BookN/A

Profitability

Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A

Miscellaneous

Employees27
OptionableNot Optionable

Biopharmx (NYSEAMERICAN:BPMX) Frequently Asked Questions

What is Biopharmx's stock symbol?

Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."

How were Biopharmx's earnings last quarter?

Biopharmx Corp (NYSEAMERICAN:BPMX) issued its quarterly earnings data on Thursday, December, 6th. The biotechnology company reported ($0.02) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.02). The biotechnology company earned $0.01 million during the quarter, compared to the consensus estimate of $0.02 million. View Biopharmx's Earnings History.

When is Biopharmx's next earnings date?

Biopharmx is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for Biopharmx.

What price target have analysts set for BPMX?

1 analysts have issued twelve-month price targets for Biopharmx's stock. Their predictions range from $1.50 to $1.50. On average, they expect Biopharmx's share price to reach $1.50 in the next year. This suggests a possible upside of 1,150.0% from the stock's current price. View Analyst Price Targets for Biopharmx.

What is the consensus analysts' recommendation for Biopharmx?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biopharmx in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biopharmx.

Has Biopharmx been receiving favorable news coverage?

News articles about BPMX stock have trended positive this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Biopharmx earned a media sentiment score of 2.8 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an effect on the company's share price in the immediate future.

Are investors shorting Biopharmx?

Biopharmx saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,768,921 shares, an increase of 12.9% from the December 14th total of 1,567,215 shares. Based on an average daily trading volume, of 3,808,899 shares, the days-to-cover ratio is currently 0.5 days. Approximately 1.0% of the company's shares are short sold. View Biopharmx's Current Options Chain.

Who are some of Biopharmx's key competitors?

Who are Biopharmx's key executives?

Biopharmx's management team includes the folowing people:
  • Dr. Kin Foong Chan, Exec. VP of Research & Technology (Age 44)
  • Dr. David S. Tierney M.D., Pres, CEO, CFO and Director (Age 54)
  • Dr. José Zayas, Sr. VP of Operations
  • Ms. Joyce Goto, VP ,CAO & Controller (Age 45)
  • Dr. R. Kehl Sink, Sr. VP of Intellectual Property & Legal

How do I buy shares of Biopharmx?

Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biopharmx's stock price today?

One share of BPMX stock can currently be purchased for approximately $0.12.

What is Biopharmx's official website?

The official website for Biopharmx is http://www.biopharmx.com.

How can I contact Biopharmx?

Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.


MarketBeat Community Rating for Biopharmx (NYSEAMERICAN BPMX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  195 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  313
MarketBeat's community ratings are surveys of what our community members think about Biopharmx and other stocks. Vote "Outperform" if you believe BPMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Featured Article: Cost of Equity

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel